BioXcel Therapeutics Files 8-K

TL;DR

BioXcel dropped an 8-K on 9/15, likely important news.

AI Summary

BioXcel Therapeutics, Inc. filed an 8-K on September 15, 2025, reporting on events that occurred on the same date. The filing is primarily a Regulation FD Disclosure and covers "Other Events" without specifying the exact nature of these events in the provided text.

Why It Matters

This 8-K filing indicates that BioXcel Therapeutics has made a disclosure to the SEC regarding significant events. Investors should review the full filing for details on what these events entail.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which typically reports material events, but the provided text lacks specifics, necessitating further investigation by investors.

Key Players & Entities

• BioXcel Therapeutics, Inc. (company) — Registrant
• September 15, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
• $8.1 million — ection with the offer and sale of up to $8.1 million shares pursuant to the ATM Program (the
• $3.5 million — ith the offer and sale of an additional $3.5 million shares pursuant to the ATM Program (the
• $80.0 million — ith the offer and sale of an additional $80.0 million shares pursuant to the ATM Program (the
• $37.3 m — 025, the Company raised an aggregate of $37.3 million, including (i) aggregate gross pr
• $27.6 million — gregate gross proceeds of approximately $27.6 million pursuant to the sale of 9,312,892 share
• $9.7 million — gregate gross proceeds of approximately $9.7 million pursuant to the exercise of outstanding

Filing Documents

• tm2526080d1_8k.htm (8-K) — 34KB
• 0001104659-25-089773.txt ( ) — 198KB
• btai-20250915.xsd (EX-101.SCH) — 3KB
• btai-20250915_lab.xml (EX-101.LAB) — 33KB
• btai-20250915_pre.xml (EX-101.PRE) — 22KB
• tm2526080d1_8k_htm.xml (XML) — 3KB

01 Regulation FD

Item 7.01 Regulation FD. On September 15, 2025, BioXcel Therapeutics, Inc. (the "Company") provided the following corporate and financing updates: Clinical Trial Update On September 13, 2025, the Company completed enrollment in its open label clinical study designed to evaluate the correlation between the patient-and informant-reported mCGI-S measurement and the Positive and Negative Syndrome Scale-Excitatory Component ("PEC") scale, conducted by trained raters. The study was designed to evaluate approximately 30 patients and the Company expects to release the results in the fourth quarter of 2025. The results from this study, along with the results of the SERENITY At-Home Pivotal Phase 3 Safety Trial already announced, will be included in the clinical package for the sNDA submission, which is expected in the first quarter of 2026. Financing and Liquidity Update On April 3, 2025, the Company entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell shares of Common Stock through any method permitted that is deemed an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, under which Canaccord Genuity LLC will act as sales agent (the "ATM Program"). The Company filed a prospectus supplement with the Securities and Exchange Commission on April 3, 2025, in connection with the offer and sale of up to $8.1 million shares pursuant to the ATM Program (the "April ATM Prospectus Supplement"). On August 6, 2025, the Company filed a further prospectus supplement with the Securities and Exchange Commission in connection with the offer and sale of an additional $3.5 million shares pursuant to the ATM Program (the "August ATM Prospectus Supplement"). As of August 18, 2025, the Company filed a further prospectus supplement with the Securities and Exchange Commission in connection with the offer and sale of an additional $80.0 million shares pursuant to the ATM Program (the "Second August ATM Prospectus Su

01 Other Events

Item 8.01 Other Events. The disclosure under Item 7.01 is included in this Item 8.01 of this Current Report on Form 8-K and incorporated herein by reference, other than the sixth paragraph.

Forward-Looking Statements

Forward-Looking Statements This current report includes "forward-looking to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this current report other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company's upcoming data release for the patient-dyad study , the planned sNDA submission, and the Company's ability to fund operating expenses and capital expenditure requirements into the first quarter of 2026 with current cash and cash equivalents. When used herein, words including "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 15, 2025 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR